Schrödinger to Present New Preclinical Data From Its MALT1 Inhibitor Program at ASH 2021 Annual Meeting
Schrödinger, Inc. (Nasdaq: SDGR) announced new preclinical data on its small-molecule MALT1 inhibitors, to be presented at the American Society of Hematology's Annual Meeting from December 11-14, 2021, in Atlanta, Georgia. MALT1 inhibitors are a promising therapeutic route for certain non-Hodgkin B-cell lymphomas and chronic lymphocytic leukemia (CLL). The lead MALT1 inhibitor is expected to enter clinical trials next year. The presentation will cover characterization details, which may enhance investor interest and highlight the company's innovative drug discovery approach.
- Presentation of promising preclinical data on MALT1 inhibitors may enhance investor confidence.
- The most advanced MALT1 inhibitor is expected to enter clinical trials in 2022.
- None.
Inhibiting MALT1 (mucosa-associated lymphoid tissue lymphoma translocation protein 1) is considered a potentially promising therapeutic approach for the treatment of certain subtypes of non-Hodgkin B-cell lymphomas and for chronic lymphocytic leukemia (CLL). Schrödinger has identified a number of small-molecule MALT1 inhibitors, the most advanced of which is expected to enter the clinic next year.
Details of the poster presentation are as follows:
Title: Characterization of Potent Paracaspase MALT1 Inhibitors for Hematological Malignancies
Abstract number: 1187
Date & time: Saturday,
Location:
About Schrödinger
Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based software platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Schrödinger’s multidisciplinary drug discovery team also leverages the software platform to advance collaborative programs and its own pipeline of novel therapeutics to address unmet medical needs.
Founded in 1990, Schrödinger has over 500 employees and is engaged with customers and collaborators in more than 70 countries. To learn more, visit www.schrodinger.com and follow us on LinkedIn and Twitter.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 including, but not limited to those regarding the expected timing of clinical trials for Schrödinger’s MALT1 inhibitor program, and the potential of MALT1 inhibitors to be used for the treatment of certain B-cell lymphomas and for chronic lymphocytic leukemia. Statements including words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intend," "look forward," "may," "might," "plan," "potential," "predict," "project," "should," "target," "will," "would" and statements in the future tense are forward-looking statements. These forward-looking statements reflect Schrödinger’s current views about its plans, intentions, expectations, strategies and prospects, which are based on the information currently available to the company and on assumptions the company has made. Actual results may differ materially from those described in these forward-looking statements and are subject to a variety of assumptions, uncertainties, risks and factors that are beyond Schrödinger’s control, including the uncertainties inherent in early stage drug development, including the conduct of research activities, the initiation and completion of preclinical studies and clinical trials; uncertainties as to the availability and timing of results from preclinical studies; the timing of and the company’s ability to submit and obtain regulatory approval for investigational new drug applications; whether results from preclinical studies will be predictive of the results of later preclinical studies and clinical trials, as well as the other risks and uncertainties identified under the caption "Risk Factors" and elsewhere in the company’s
View source version on businesswire.com: https://www.businesswire.com/news/home/20211104005073/en/
Investors:
Schrödinger, Inc.
jaren.madden@schrodinger.com
617-286-6264
Media:
Schrödinger, Inc.
tracy.lessor@schrodinger.com
617-519-9827
Source: Schrödinger, Inc.
FAQ
What is the focus of Schrödinger's MALT1 inhibitor research?
When and where will Schrödinger present its MALT1 inhibitors data?
What is the significance of the upcoming clinical trials for MALT1 inhibitors?
How might the MALT1 inhibitors impact Schrödinger's stock performance?
